1
|
Plant H, Hensley P, Holdgate G, Jonsen P, Wigglesworth M. Evaluation of the Use of Cold Plasma for Microtiter Plate Cleaning to Reduce Plastic Biohazard Waste. SLAS Technol 2020; 26:399-407. [PMID: 33252990 DOI: 10.1177/2472630320973956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Plastic pollution is the accumulation of plastic objects in the Earth's environment and is a global problem of increasing importance. The laboratory and health care industries contribute to this problem by the widely accepted single use of plastics, including microtiter plates used for compound testing. At AstraZeneca, we predict the use of more than 45,000 384-well and more than 11,000 1536-well microtiter plates per year. IonField Systems has developed a microplate cleaning system (MCS) powered by PlasmaKnife technology that uses cold plasma to clean microtiter plates. AstraZeneca proposed the use of this system for standard ANSI (https://slas.org/resources/information/industry-standards/) microtiter plate regeneration. Here we present the results of an evaluation using a model system involving the cleaning of plates following an enzyme-based biochemical assay, as well as the software and hardware enhancements that were incorporated into the production PlasmaKnife MCS. The method involved determining the level of inhibition achieved by residual compound following different cleaning protocols and showed that cleaning achieved in about 2 min was sufficient to remove trace compound contamination. Future work will focus on assessing the number of regeneration cycles that can be reliably achieved.
Collapse
Affiliation(s)
- Helen Plant
- Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Alderley Park, UK
| | | | - Geoffrey Holdgate
- Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Alderley Park, UK
| | | | - Mark Wigglesworth
- Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Alderley Park, UK
| |
Collapse
|
2
|
Kepiro M, Varkuti BH, Davis RL. High Content, Phenotypic Assays and Screens for Compounds Modulating Cellular Processes in Primary Neurons. Methods Enzymol 2018; 610:219-250. [PMID: 30390800 DOI: 10.1016/bs.mie.2018.09.021] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
High content, phenotypic screens offer a powerful approach to systems biology at the cellular level. The approach employs cells carrying fluorescently labeled molecules or organelles in 384- or 1536-well microplates, and an automated confocal screening microscope for capturing images from each well. Although some specifics vary according to the assay type, each will apply some degree of image processing and feature extraction followed by a data analysis pipeline to identify the perturbations (small molecules, etc.) of interest. We describe and discuss the advantages and limitations of high content assays and screens using the specific example of assaying mitochondrial dynamics in primary neurons. We provide a detailed description of our culturing methods, imaging and data analysis techniques and provide an open source, ready to use CellProfiler pipeline for high-throughput image segmentation and quantification tool for mitochondrial parameters.
Collapse
Affiliation(s)
- Miklos Kepiro
- Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, FL, United States
| | - Boglarka H Varkuti
- Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, FL, United States
| | - Ronald L Davis
- Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, FL, United States.
| |
Collapse
|
3
|
Dawes TD, Turincio R, Jones SW, Rodriguez RA, Gadiagellan D, Thana P, Clark KR, Gustafson AE, Orren L, Liimatta M, Gross DP, Maurer T, Beresini MH. Compound Transfer by Acoustic Droplet Ejection Promotes Quality and Efficiency in Ultra-High-Throughput Screening Campaigns. ACTA ACUST UNITED AC 2016; 21:64-75. [DOI: 10.1177/2211068215590588] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2015] [Indexed: 11/17/2022]
|
4
|
Roberts K, Callis R, Ikeda T, Paunovic A, Simpson C, Tang E, Turton N, Walker G. Implementation and Challenges of Direct Acoustic Dosing into Cell-Based Assays. ACTA ACUST UNITED AC 2015; 21:76-89. [PMID: 26169025 DOI: 10.1177/2211068215595212] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2015] [Indexed: 12/18/2022]
Abstract
Since the adoption of Labcyte Echo Acoustic Droplet Ejection (ADE) technology by AstraZeneca in 2005, ADE has become the preferred method for compound dosing into both biochemical and cell-based assays across AstraZeneca research and development globally. The initial implementation of Echos and the direct dosing workflow provided AstraZeneca with a unique set of challenges. In this article, we outline how direct Echo dosing has evolved over the past decade in AstraZeneca. We describe the practical challenges of applying ADE technology to 96-well, 384-well, and 1536-well assays and how AstraZeneca developed and applied software and robotic solutions to generate fully automated and effective cell-based assay workflows.
Collapse
Affiliation(s)
| | | | - Tim Ikeda
- AstraZeneca, Gatehouse Park, Boston, MA, USA
| | | | | | - Eric Tang
- AstraZeneca PLC, Alderley Park, Cheshire, UK
| | - Nick Turton
- AstraZeneca PLC, Alderley Park, Cheshire, UK
| | | |
Collapse
|
5
|
Elkin LL, Harden DG, Saldanha S, Ferguson H, Cheney DL, Pieniazek SN, Maloney DP, Zewinski J, O’Connell J, Banks M. Just-in-Time Compound Pooling Increases Primary Screening Capacity without Compromising Screening Quality. ACTA ACUST UNITED AC 2015; 20:577-87. [DOI: 10.1177/1087057115572988] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2014] [Accepted: 01/20/2015] [Indexed: 11/16/2022]
Abstract
Compound pooling, or multiplexing more than one compound per well during primary high-throughput screening (HTS), is a controversial approach with a long history of limited success. Many issues with this approach likely arise from long-term storage of library plates containing complex mixtures of compounds at high concentrations. Due to the historical difficulties with using multiplexed library plates, primary HTS often uses a one-compound–one-well approach. However, as compound collections grow, innovative strategies are required to increase the capacity of primary screening campaigns. Toward this goal, we have developed a novel compound pooling method that increases screening capacity without compromising data quality. This method circumvents issues related to the long-term storage of complex compound mixtures by using acoustic dispensing to enable “just-in-time” compound pooling directly in the assay well immediately prior to assay. Using this method, we can pool two compounds per well, effectively doubling the capacity of a primary screen. Here, we present data from pilot studies using just-in-time pooling, as well as data from a large >2-million-compound screen using this approach. These data suggest that, for many targets, this method can be used to vastly increase screening capacity without significant reduction in the ability to detect screening hits.
Collapse
Affiliation(s)
- L. L. Elkin
- Department of Lead Discovery & Optimization, Bristol-Myers Squibb, Wallingford, CT, USA
| | - D. G. Harden
- Department of Lead Discovery & Optimization, Bristol-Myers Squibb, Wallingford, CT, USA
| | | | - H. Ferguson
- Department of Lead Discovery & Optimization, Bristol-Myers Squibb, Wallingford, CT, USA
| | - D. L. Cheney
- Department of Molecular Structure & Design, Bristol-Myers Squibb, Pennington, NJ, USA
| | - S. N. Pieniazek
- Department of Molecular Structure & Design, Bristol-Myers Squibb, Pennington, NJ, USA
| | - D. P. Maloney
- Department of Lead Discovery & Optimization, Bristol-Myers Squibb, Wallingford, CT, USA
| | - J. Zewinski
- Department of Lead Discovery & Optimization, Bristol-Myers Squibb, Wallingford, CT, USA
| | | | - M. Banks
- Department of Lead Discovery & Optimization, Bristol-Myers Squibb, Wallingford, CT, USA
| |
Collapse
|
6
|
Zhang JH, Kang ZB, Ardayfio O, Ho PI, Smith T, Wallace I, Bowes S, Hill WA, Auld DS. Application of Titration-Based Screening for the Rapid Pilot Testing of High-Throughput Assays. ACTA ACUST UNITED AC 2013; 19:651-60. [DOI: 10.1177/1087057113512151] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Accepted: 10/18/2013] [Indexed: 01/20/2023]
Abstract
Pilot testing of an assay intended for high-throughput screening (HTS) with small compound sets is a necessary but often time-consuming step in the validation of an assay protocol. When the initial testing concentration is less than optimal, this can involve iterative testing at different concentrations to further evaluate the pilot outcome, which can be even more time-consuming. Quantitative HTS (qHTS) enables flexible and rapid collection of assay performance statistics, hits at different concentrations, and concentration-response curves in a single experiment. Here we describe the qHTS process for pilot testing in which eight-point concentration-response curves are produced using an interplate asymmetric dilution protocol in which the first four concentrations are used to represent the range of typical HTS screening concentrations and the last four concentrations are added for robust curve fitting to determine potency/efficacy values. We also describe how these data can be analyzed to predict the frequency of false-positives, false-negatives, hit rates, and confirmation rates for the HTS process as a function of screening concentration. By taking into account the compound pharmacology, this pilot-testing paradigm enables rapid assessment of the assay performance and choosing the optimal concentration for the large-scale HTS in one experiment.
Collapse
Affiliation(s)
- Ji-Hu Zhang
- Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Zhao B. Kang
- Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Ophelia Ardayfio
- Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Pei-i Ho
- Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Thomas Smith
- Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Iain Wallace
- Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Scott Bowes
- Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - W. Adam Hill
- Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Douglas S. Auld
- Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| |
Collapse
|
7
|
Henrich CJ, Beutler JA. Matching the power of high throughput screening to the chemical diversity of natural products. Nat Prod Rep 2013; 30:1284-98. [PMID: 23925671 PMCID: PMC3801163 DOI: 10.1039/c3np70052f] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Covering up to 2013. Application of high throughput screening technologies to natural product samples demands alterations in assay design as well as sample preparation in order to yield meaningful hit structures at the end of the campaign.
Collapse
Affiliation(s)
- Curtis J. Henrich
- Basic Science Program, SAIC-Frederick, Inc. Frederick National Lab
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702 USA
| | - John A. Beutler
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702 USA
| |
Collapse
|
8
|
Martinez JP, Hinkelmann B, Fleta-Soriano E, Steinmetz H, Jansen R, Diez J, Frank R, Sasse F, Meyerhans A. Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay. Microb Cell Fact 2013; 12:85. [PMID: 24063434 PMCID: PMC3852058 DOI: 10.1186/1475-2859-12-85] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Accepted: 09/19/2013] [Indexed: 11/24/2022] Open
Abstract
Background Drug-resistance and therapy failure due to drug-drug interactions are the main challenges in current treatment against Human Immunodeficiency Virus (HIV) infection. As such, there is a continuous need for the development of new and more potent anti-HIV drugs. Here we established a high-throughput screen based on the highly permissive TZM-bl cell line to identify novel HIV inhibitors. The assay allows discriminating compounds acting on early and/or late steps of the HIV replication cycle. Results The platform was used to screen a unique library of secondary metabolites derived from myxobacteria. Several hits with good anti-HIV profiles were identified. Five of the initial hits were tested for their antiviral potency. Four myxobacterial compounds, sulfangolid C, soraphen F, epothilon D and spirangien B, showed EC50 values in the nM range with SI > 15. Interestingly, we found a high amount of overlapping hits compared with a previous screen for Hepatitis C Virus (HCV) using the same library. Conclusion The unique structures and mode-of-actions of these natural compounds make myxobacteria an attractive source of chemicals for the development of broad-spectrum antivirals. Further biological and structural studies of our initial hits might help recognize smaller drug-like derivatives that in turn could be synthesized and further optimized.
Collapse
Affiliation(s)
- Javier P Martinez
- Infection Biology Group, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Robotic implementation of assays: tissue-nonspecific alkaline phosphatase (TNAP) case study. Methods Mol Biol 2013. [PMID: 23860647 DOI: 10.1007/978-1-62703-562-0_4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register]
Abstract
Laboratory automation and robotics have "industrialized" the execution and completion of large-scale, enabling high-capacity and high-throughput (100 K-1 MM/day) screening (HTS) campaigns of large "libraries" of compounds (>200 K-2 MM) to complete in a few days or weeks. Critical to the success these HTS campaigns is the ability of a competent assay development team to convert a validated research-grade laboratory "benchtop" assay suitable for manual or semi-automated operations on a few hundreds of compounds into a robust miniaturized (384- or 1,536-well format), well-engineered, scalable, industrialized assay that can be seamlessly implemented on a fully automated, fully integrated robotic screening platform for cost-effective screening of hundreds of thousands of compounds. Here, we provide a review of the theoretical guiding principles and practical considerations necessary to reduce often complex research biology into a "lean manufacturing" engineering endeavor comprising adaption, automation, and implementation of HTS. Furthermore we provide a detailed example specifically for a cell-free in vitro biochemical, enzymatic phosphatase assay for tissue-nonspecific alkaline phosphatase that illustrates these principles and considerations.
Collapse
|
10
|
Ho PI, Yue K, Pandey P, Breault L, Harbinski F, McBride AJ, Webb B, Narahari J, Karassina N, Wood KV, Hill A, Auld DS. Reporter enzyme inhibitor study to aid assembly of orthogonal reporter gene assays. ACS Chem Biol 2013; 8:1009-17. [PMID: 23485150 DOI: 10.1021/cb3007264] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Reporter gene assays (RGAs) are commonly used to measure biological pathway modulation by small molecules. Understanding how such compounds interact with the reporter enzyme is critical to accurately interpret RGA results. To improve our understanding of reporter enzymes and to develop optimal RGA systems, we investigated eight reporter enzymes differing in brightness, emission spectrum, stability, and substrate requirements. These included common reporter enzymes such as firefly luciferase (Photinus pyralis), Renilla reniformis luciferase, and β-lactamase, as well as mutated forms of R. reniformis luciferase emitting either blue- or green-shifted luminescence, a red-light emitting form of Luciola cruciata firefly luciferase, a mutated form of Gaussia princeps luciferase, and a proprietary luciferase termed "NanoLuc" derived from the luminescent sea shrimp Oplophorus gracilirostris. To determine hit rates and structure-activity relationships, we screened a collection of 42,460 PubChem compounds at 10 μM using purified enzyme preparations. We then compared hit rates and chemotypes of actives for each enzyme. The hit rates ranged from <0.1% for β-lactamase to as high as 10% for mutated forms of Renilla luciferase. Related luciferases such as Renilla luciferase mutants showed high degrees of inhibitor overlap (40-70%), while unrelated luciferases such as firefly luciferases, Gaussia luciferase, and NanoLuc showed <10% overlap. Examination of representative inhibitors in cell-based assays revealed that inhibitor-based enzyme stabilization can lead to increases in bioluminescent signal for firefly luciferase, Renilla luciferase, and NanoLuc, with shorter half-life reporters showing increased activation responses. From this study we suggest strategies to improve the construction and interpretation of assays employing these reporter enzymes.
Collapse
Affiliation(s)
| | | | | | | | | | - Aaron J. McBride
- Thermo Fisher Scientific, Rockford, Illinois, 61105-0117, United
States
| | - Brian Webb
- Thermo Fisher Scientific, Rockford, Illinois, 61105-0117, United
States
| | - Janaki Narahari
- Thermo Fisher Scientific, Rockford, Illinois, 61105-0117, United
States
| | | | - Keith V. Wood
- Promega Corporation, Madison, Wisconsin, 53711, United States
| | | | | |
Collapse
|